P
Pfizer
Prescription medicines, vaccines and consumer products
About Pfizer
Pfizer Inc. is a leading biopharmaceutical company that focuses on the discovery, development, and manufacture of healthcare products. Operating in the global healthcare market, Pfizer serves a diverse range of clients including governments, healthcare providers, and patients. The company’s business model revolves around the research and development of innovative medicines and vaccines, which are then commercialized and distributed worldwide. Pfizer generates revenue through the sale of its pharmaceutical products, which include vaccines, oncology treatments, and other specialized medicines. The company has been at the forefront of the fight against COVID-19, partnering with BioNTech to develop and distribute a highly effective vaccine. Pfizer's commitment to public health is further demonstrated by its initiatives to provide vaccines to underserved populations. The company continues to expand its portfolio with new approvals and authorizations for various treatments, ensuring a steady pipeline of future products.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1849
- Headquarters
- New York City, United States
- Listing
- IPO 1983
- Employees
- 108,228
- Open positions
- None listed
- Dealroom signal
- 75.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Horizon Europe
- Business model
- Manufacturing, Marketplace & ecommerce
- Client focus
- b2b, b2c
- Investment activity
- 122 companies, latest May 2026
- Capital deployed
- $3.8B
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | May 2025 | $3.6B | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Oct 2024 | $1B | — | Starboard Value | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Pfizer is 1.2M monthly website visits, up 39.5% over the last three months. Pfizer's team declined 6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CellCentricCambridge, United KingdomOral p300/CBP inhibitor for targeted cancer therapy
$880Mvaluation
Enodia TherapeuticsParis, FranceAI-driven small molecules targeting protein secretion degradation.
$91Mvaluation
SB
Syneron BioChinaAI-powered macrocyclic peptide drug discovery platform
$600Mvaluation
MetseraNew York City, United StatesMetsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases
$4.9Bvaluation
MindImmune TherapeuticsProvidence, United StatesDrugs which treat diseases of the central nervous system
$41Mvaluation
Meta-fluxDublin, IrelandMeta-flux is an AI biologist for pharmaceutical drug development.
$7.9Mvaluation
3SBioShenyang, China3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing
$2.8Bvaluation
TRIMTECH TherapeuticsCambridge, United KingdomDeveloping small molecule degraders targeting protein aggregates for neurodegenerative and inflammatory disorders
$56Mvaluation
NormunityNew Haven, United StatesA biotechnology business that develops cutting-edge, precise immunotherapies for cancer
$300Mvaluation
Babycue PrivateBhubaneswar Municipal Corporation, IndiaMicrofluidic paper-based diagnostics for early detection and differentiation of diarrheal infections at point of care
→
Enara BioOxford, United KingdomIlluminating the immune interface to develop new cancer therapies - Enara Bio
$130Mvaluation
CytoreasonTel Aviv-Yafo, IsraelTurns human clinical data into clear biology, to deliver data-driven target discovery and drug development
$320Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
HHS Administration for Strategic Preparedness and Response
Series B and later1 investor entered at this stage
Starboard Value
Other known investors4 additional known investors
Aisling Capital
ARCH Venture Partners
Foresite Capital
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pfizer on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pfizer’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.